Searching for indicators of malignancy in pancreatic intraductal papillary mucinous neoplasms: The value of 18FDG-PET confirmed

Annals of Surgical Oncology

Volumn 19, Issue 11, 2012, Pages 3574-3580

  Baiocchi, Gian Luca ^a   Bertagna, Francesco ^a   Gheza, Federico ^a   Grazioli, Luigi ^b   Calanducci, David ^a   Giubbini, Raffaele ^a   Portolani, Nazario ^a   Giulini, Stefano M ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b BRESCIA CIVIL HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; BACKACHE; BENIGN TUMOR; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; GASTROINTESTINAL TUMOR; HUMAN; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; JAUNDICE; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MALE; MALIGNANT NEOPLASTIC DISEASE; MALIGNANT TRANSFORMATION; PANCREAS RESECTION; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; SENSITIVITY AND SPECIFICITY; TUMOR LOCALIZATION; TUMOR VOLUME; WEIGHT REDUCTION;

ADENOCARCINOMA, MUCINOUS; ADENOCARCINOMA, PAPILLARY; ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; CONFIDENCE INTERVALS; FLUORODEOXYGLUCOSE F18; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; ODDS RATIO; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RADIOPHARMACEUTICALS;

EID: 84868193554     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-012-2234-5     Document Type: Article

References (32)

1. Brugge WR, Lewandrowski K, Lee-Lewandrowski E, Centeno BA, Szydlo T, Regan S, et al. Diagnosis of pancreatic cystic neoplasms: A report of the Cooperative Pancreatic Cyst Study. Gastroenterology. 2004;126:1330-6. (Pubitemid 38552797)
2. Longnecker DS, Hruban RH, Kloppel G. Intraductal-papillary mucinous neoplasms of the pancreas. In: Hamilton SR, Aaltonen LA, editors. World Health Organization classification of tumors. Pathology and genetics of tumors of the digestive system. Lyon: IARC Press; 2000. p. 237-40.
3. Obara T, Maguchi H, Saitoh Y, Itoh A, Arisato S, Ashida T, et al. Mucin-producing tumor of the pancreas: Natural history and serial pancreatogram changes. Am J Gastroenterol. 1993;88:564-9. (Pubitemid 23106594)
4. Wang SE, Shyr YM, Chen TH, Su CH, Hwang TL, Jeng KS, et al. Comparison of resected and non-resected intraductal papillary mucinous neoplasms of the pancreas. World J Surg. 2005;29:1650-7.
5. Hirono S, Tani M, Kawai M, Ina S, Nishioka R, Miyazawa M, et al. Treatment strategy for intraductal papillary mucinous neoplasm of the pancreas based on malignant predictive factors. Arch Surg. 2009;144:345-9.
6. Maire F, Hammel P, Terris B, Paye F, Scoazec JY, Cellier C, et al. Prognosis of malignant intraductal papillary mucinous tumors of the pancreas after surgical resection: Comparison with pancreatic ductal adenocarcinoma. Gut. 2002;51:717-22. (Pubitemid 35216862)
7. Wada K, Kozarek RA, Traverso LW. Outcomes following resection of invasive and noninvasive intraductal papillary mucinous neoplasms of the pancreas. Am J Surg. 2005;189:632-7. (Pubitemid 40602958)
8. Sawhney MS, Al-Bashir S, Cury MS, Brown A, Chuttani R, Pleskow DK, et al. International consensus guidelines for surgical resection of mucinous neoplasms cannot be applied to all cystic lesions of the pancreas. Clin GastroenterolHepatol. 2009;7:1373-6.
9. Pelaez-Luna M, Chari ST, Smyrk TC, Takahashi N, Clain JE, Levy MJ, et al. Do consensus indications for resection in branch duct intraductal papillary mucinous neoplasm predict malignancy? A study of 147 patients. Am J Gastroenterol. 2007;102: 1759-64. (Pubitemid 47206677)
10. Tanaka M, Chari S, Adsay V, Fernandez-del Castillo C, Falconi M, Shimizu M, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology. 2006;6:17-32.
11. Takanami K, Hiraide T, Tsuda M, Nakamura Y, Kaneta T, Takase K, et al. Additional value of FDG PET/CT to contrastenhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules. Ann Nucl Med. 2011;25:501-10.
12. Hong HS, Yun M, Cho A, Choi JY, Kim MJ, Kim KW, et al. The utility of F-18 FDG PET/CT in the evaluation of pancreatic intraductal papillary mucinous neoplasm. Clin Nucl Med. 2010;35:776-9.
13. Tomimaru Y, Takeda Y, Tatsumi M, Kim T, Kobayashi S, Marubashi S, et al. Utility of 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography in differential diagnosis of benign and malignant intraductal papillary-mucinous neoplasm of the pancreas. Oncol Rep. 2010;24:613-20.
14. Baiocchi GL, Portolani N, Bertagna F, Gheza F, Pizzocaro C, Giubbini R, et al. Possible additional value of 18FDG-PET in managing pancreas intraductal papillary mucinous neoplasms: Preliminary results. J Exp Clin Cancer Res. 2008;27:10-5.
15. Schmidt CM, White PB, Waters JA, Yiannoutsos CT, Cummings OW, Baker M, et al. Intraductal papillary mucinous neoplasms: Predictors of malignant and invasive pathology. Ann Surg. 2007;246:644-51. (Pubitemid 47480616)
16. Sugiyama M, Izumisato Y, Abe N, Masaki T, Mori T, Atomi Y, et al. Predictive factors for malignancy in intraductal papillarymucinous tumors of the pancreas. Br J Surg. 2003;90:1244-9. (Pubitemid 37330429)
17. Shin SH, Han DJ, Park KT, Kim YH, Park JB, Kim SC. Validating a simple scoring system to predict malignancy and invasiveness of intraductal papillary mucinous neoplasms of the pancreas. World J Surg. 2010 34:776-83.
18. Kawai M, Uchiyama K, Tani M, Onishi H, Kinoshita H, Ueno M, et al. Clinicopathological features ofmalignant intraductal papillary mucinous tumors of the pancreas. Arch Surg. 2004;139:188-92.
19. Falconi M, Salvia R, Bassi C, Zamboni G, Talamini G, Pederzoli P. Clinicopathological features and treatment of intraductalpapillary mucinous tumours of the pancreas. Br J Surg. 2001;88: 376-81. (Pubitemid 32238699)
20. Salvia R, Crippa S, Falconi M, Bassi C, Guarise A, Scarpa A, et al. Branch-duct intraductal papillary mucinous neoplasms of the pancreas: To operate or not to operate? Gut. 2007;56:1086-90. (Pubitemid 47123238)
21. Jang JY, Kim SW, Ahn YJ, Yoon YS, Choi MG, Lee KU, et al. Multicenter analysis of clinicopathologic features of intraductal papillary mucinous tumor of the pancreas: Is it possible to predict the malignancy before surgery? Ann Surg Oncol. 2005;12:124-32. (Pubitemid 40486620)
22. Baiocchi GL, Portolani N, Missale G, Baronchelli C, Gheza F, Cantu M, et al. Intraductal papillary mucinous neoplasm of the pancreas (IPMN): Clinico-pathological correlations and surgical indications. World J Surg Oncol. 2010;8:25-31.
23. Winter JM, Cameron JL, Campbell KA, Arnold MA, Chang DC, Coleman J, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: A single-institution experience. JGastrointest Surg. 2006;10: 1199-211. (Pubitemid 44781200)
24. Waters JA, Schmidt CM, Pinchot JW, White PB, Cummings OW, Pitt HA, et al. CT vs MRCP: Optimal classification of IPMN type and extent. J Gastrointest Surg. 2008;12:101-9.
25. Berberat P, Freiss H, Kashiwagi M, Beger HG, Buchler MW. Diagnosis and staging of pancreatic cancer by positron emission tomography. World J Surg. 1999;23:882-7. (Pubitemid 29398467)
26. Mansour JC, Schwartz L, Pandit-Taskar N, D'Angelica M, Fong Y, Larson SM, et al. The utility of F-18 fluorodeoxyglucose whole body PET imaging for determining malignancy in cystic lesions of the pancreas. J Gastrointest Surg. 2006;10:1354-60. (Pubitemid 44908996)
27. Sperti C, Pasquali C, Decet G. F-18-fluorodeoxyglucose positron emission tomography in differentiating malignant from benign pancreatic cysts: A prospective study. J Gastrointest Surg. 2005;9: 22-8.
28. Yoshioka M, Sato T, Furuya T, Shibata S, Andoh H, Asanuma Y, et al. Positron emission tomography with 2-deoxy-2-[(18)F] fluoro- d-glucose for diagnosis of intraductal papillary mucinous tumor of the pancreas with parenchymal invasion. J Gastroenterol. 2003;38:1189-93. (Pubitemid 38128834)
29. Goh BK, Chung YF, Ng DC, Selvarajan S, Soo KC. Positron emission tomography with 2-deoxy-2-[18F] fluoro-D-glucose in the detection of malignancy in intraductal papillary mucinous neoplasms of the pancreas. JOP. 2007;8:350-4. (Pubitemid 46876796)
30. Sperti C, Bissoli S, Pasquali C, Frison L, Liessi G, Chierichetti F, et al. 18-Fluorodeoxyglucose positron emission tomography enhances computed tomography diagnosis of malignant intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2007;246:932-7. (Pubitemid 350179174)
31. Reid-Lombardo KM, Mathis KL, Wood CM, Harmsen WS, Sarr MG. Frequency of extrapancreatic neoplasms in intraductal papillary mucinous neoplasm of the pancreas: Implications for management. Ann Surg. 2010;251:64-9.
32. Ikeuchi N, Itoi T, Sofuni A, Itokawa F, Tsuchiya T, Kurihara T, et al. Prognosis of cancer with branch duct type IPMN of the pancreas. World J Gastroenterol. 2010;16:1890-5.